395 related articles for article (PubMed ID: 29146244)
1. Extending antigen release from particulate vaccines results in enhanced antitumor immune response.
Kapadia CH; Tian S; Perry JL; Sailer D; Christopher Luft J; DeSimone JM
J Control Release; 2018 Jan; 269():393-404. PubMed ID: 29146244
[TBL] [Abstract][Full Text] [Related]
2. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
3. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
Front Immunol; 2018; 9():2968. PubMed ID: 30631324
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
Karan D; Krieg AM; Lubaroff DM
Int J Cancer; 2007 Oct; 121(7):1520-8. PubMed ID: 17565748
[TBL] [Abstract][Full Text] [Related]
6. Cross-Linked Peptide Nanoclusters for Delivery of Oncofetal Antigen as a Cancer Vaccine.
Tsoras AN; Champion JA
Bioconjug Chem; 2018 Mar; 29(3):776-785. PubMed ID: 29436221
[TBL] [Abstract][Full Text] [Related]
7. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
8. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
[TBL] [Abstract][Full Text] [Related]
9. Cascade Cytosol Delivery of Dual-Sensitive Micelle-Tailored Vaccine for Enhancing Cancer Immunotherapy.
Jiang D; Mu W; Pang X; Liu Y; Zhang N; Song Y; Garg S
ACS Appl Mater Interfaces; 2018 Nov; 10(44):37797-37811. PubMed ID: 30360105
[TBL] [Abstract][Full Text] [Related]
10. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
[TBL] [Abstract][Full Text] [Related]
11. Improved vaccine-induced immune responses via a ROS-triggered nanoparticle-based antigen delivery system.
Liang X; Duan J; Li X; Zhu X; Chen Y; Wang X; Sun H; Kong D; Li C; Yang J
Nanoscale; 2018 May; 10(20):9489-9503. PubMed ID: 29675543
[TBL] [Abstract][Full Text] [Related]
12. Cell Penetrating Peptide-Based Redox-Sensitive Vaccine Delivery System for Subcutaneous Vaccination.
Wang K; Yang Y; Xue W; Liu Z
Mol Pharm; 2018 Mar; 15(3):975-984. PubMed ID: 29359945
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines.
Zhang TT; Kang TH; Ma B; Xu Y; Hung CF; Wu TC
Vaccine; 2012 Jan; 30(4):784-93. PubMed ID: 22120194
[TBL] [Abstract][Full Text] [Related]
15. Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development.
Han JA; Kang YJ; Shin C; Ra JS; Shin HH; Hong SY; Do Y; Kang S
Nanomedicine; 2014 Apr; 10(3):561-9. PubMed ID: 24262997
[TBL] [Abstract][Full Text] [Related]
16. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.
Wafa EI; Geary SM; Goodman JT; Narasimhan B; Salem AK
Acta Biomater; 2017 Mar; 50():417-427. PubMed ID: 28063991
[TBL] [Abstract][Full Text] [Related]
17. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.
Miura N; Akita H; Tateshita N; Nakamura T; Harashima H
Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573
[TBL] [Abstract][Full Text] [Related]
18. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles.
Varypataki EM; Silva AL; Barnier-Quer C; Collin N; Ossendorp F; Jiskoot W
J Control Release; 2016 Mar; 226():98-106. PubMed ID: 26876760
[TBL] [Abstract][Full Text] [Related]
19. Harnessing self-assembling peptide nanofibers toprime robust tumor-specific CD8 T cell responses in mice.
Mohseninia A; Dehghani P; Bargahi A; Rad-Malekshahi M; Rahimikian R; Movahed A; Reza Farzaneh M; Mohammadi M
Int Immunopharmacol; 2022 Mar; 104():108522. PubMed ID: 35032825
[TBL] [Abstract][Full Text] [Related]
20. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy.
Zhang C; Shi G; Zhang J; Song H; Niu J; Shi S; Huang P; Wang Y; Wang W; Li C; Kong D
J Control Release; 2017 Jun; 256():170-181. PubMed ID: 28414151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
